Image

Preoperative Neutrophil-to-Albumin Ratio and Post-Induction Hemodynamic Vulnerability in Major Oncologic Surgery

Preoperative Neutrophil-to-Albumin Ratio and Post-Induction Hemodynamic Vulnerability in Major Oncologic Surgery

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This prospective observational study aims to evaluate whether the preoperative neutrophil percentage-to-albumin ratio (NPAR) is associated with post-induction hemodynamic vulnerability in adult patients undergoing elective major oncologic surgery under general anesthesia.

NPAR will be calculated from routine preoperative laboratory results by dividing the neutrophil percentage by the serum albumin level. No additional laboratory tests, medications, invasive procedures, or changes in anesthesia management will be performed for the purposes of the study.

Demographic characteristics, preoperative laboratory values, anesthetic data, and hemodynamic measurements will be recorded prospectively. Hemodynamic status will be evaluated during the period between induction of general anesthesia and surgical incision, with a maximum observation period of 20 minutes. Vasopressor use and administered doses will also be recorded.

The study will assess the ability of preoperative NPAR to identify patients who may be more susceptible to early hemodynamic instability following induction of general anesthesia.

Description

This is a prospective, observational, non-interventional study involving adult patients undergoing elective major oncologic surgery under general anesthesia. The study is designed to evaluate the relationship between the preoperative neutrophil percentage-to-albumin ratio (NPAR) and post-induction hemodynamic vulnerability.

A total of 220 patients are planned to be enrolled using consecutive sampling. Eligible participants will be adults aged 18 years or older who are scheduled for elective major oncologic surgery under general anesthesia, have available preoperative complete blood count and serum albumin measurements, and undergo standard hemodynamic monitoring.

NPAR will be calculated by dividing the preoperative neutrophil percentage by the serum albumin concentration in g/dL. Demographic characteristics, ASA physical status, comorbidities, preoperative laboratory values, baseline hemodynamic measurements, induction-related data, intraoperative fluid administration, and vasopressor use and doses will be recorded prospectively.

Hemodynamic measurements will be evaluated from induction of general anesthesia until surgical incision, with a maximum observation period of 20 minutes. Participants will be classified according to the presence or absence of post-induction hemodynamic vulnerability.

The study will not alter routine anesthetic or surgical management. No additional medication, laboratory test, invasive procedure, or treatment modification will be performed for research purposes. Anesthetic agents, fluid therapy, and vasopressor administration will be determined by the responsible anesthesia team according to routine clinical practice.

The predictive performance of NPAR will be evaluated using receiver operating characteristic curve analysis and the area under the curve. Multivariable logistic regression analysis will be used to examine the association between NPAR and post-induction hemodynamic vulnerability while accounting for relevant clinical variables.

Eligibility

Inclusion Criteria:

  • Age 18 years or older
  • Scheduled for elective major oncologic surgery
  • Undergoing surgery under general anesthesia
  • Availability of preoperative complete blood count and serum albumin -measurements
  • Standard hemodynamic monitoring
  • Provision of written informed consent for participation in the study

Exclusion Criteria:

  • Age younger than 18 years
  • Emergency surgery
  • Preoperative hemodynamic instability
  • Preoperative vasopressor or inotropic support
  • Sepsis or active infection
  • Hematologic malignancy
  • Advanced cardiac, renal, or hepatic failure
  • Pregnancy
  • Missing preoperative laboratory data -Inability to complete the 20-minute post-induction evaluation period-

Study details
    Hemodynamic Instability
    Post-induction Hypotension (PIH)

NCT07804706

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

5 September 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.